Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi's Diabetes Sales Force Increase Not Due To Threat From Exubera Or Levemir, Exec Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi attributes its increased detailing focus on the diabetes market to changing prescribing trends, not increased competition.

You may also be interested in...

Pfizer Breathes Easy: FDA Approves Exubera

Pfizer's Exubera is the first inhaled insulin to clear FDA; labeling recommends lung function testing.

Novo Nordisk Emphasizes Levemir “Predictability”

Planned second quarter launch would be nearly one year after FDA approval.

Pfizer Banking On Exubera Approval

The firm acquires Sanofi-Aventis’ rights to the inhaled insulin product through a change-in-control clause.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts